Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDRXLL)

Drug Name
ASP3082 Drug Info
Indication
Disease Entry ICD 11 Status REF
Aggressive cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMDRXLL

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
KRas D816V mutant (KRAS D816V) TTLJX8E RASK_HUMAN Degrader [2]

References

1 ClinicalTrials.gov (NCT05382559) A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation. U.S.National Institutes of Health.
2 Protein degraders enter the clinic - a new approach to cancer therapy. Nat Rev Clin Oncol. 2023 Apr;20(4):265-278.